2024-515218-42-00CompletedPhase 1
A first-in-human study to determine the safety and tolerability of different doses of GEH200520 Injection and GEH200521 (18F) Injection and their uses in positron emission tomography imaging for patients with cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Jun 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 14 Jun 2024
- Start date
- 23 Jan 2025
- Lead sponsor
- GE Healthcare Limited
- Diseases
- Head and neck cancer
- EU CT number
- 2024-515218-42-00
- EudraCT number
- 2022-000246-16
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 50
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stichting Amsterdam UMC | Amsterdam | Netherlands | Completed |
| Universitair Medisch Centrum Groningen | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.